Journal
JOURNAL OF IMMUNOLOGY
Volume 180, Issue 9, Pages 6392-6401Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.180.9.6392
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA050633, CA 50633, CA 06927, P30 CA006927, R01 CA050633-19A1, R01 CA083859, CA 083859] Funding Source: Medline
- NIAID NIH HHS [R01 AI050656, AI 050656] Funding Source: Medline
Ask authors/readers for more resources
Human NK cells lyse Ab-coated target cells through the process of Ab-dependent cellular cytotoxicity (ADCC). Improving ADCC responses is desirable because it is thought to be an important antitumor mechanism for some Abs. NK cell inhibitory receptors, such as killer cell Ig-like receptors, engage with MHC class I molecules on self-cells to block NK cell activation. Accordingly, we enhanced ADCC responses by blocking NK cell inhibitory receptors, thus perturbing induction of the self-recognition signal. In a cell line model of anti-lymphoma therapy, the combination of rituximab with an Ab that blocks inhibitory self-recognition yielded increased NK cell-mediated target cell lysis when compared with rituximab alone. To validate this proof-of-concept, we then used a more representative approach in which an individual's fresh primary NK cells encountered autologous, EBV-transformed B cells. In this system, rituximab and a combination of Abs that block NK cell inhibitory receptors yielded improved NK cell-mediated lysis over rituximab alone. The results show, for the first time, that disruption of inhibitory self-recognition can efficiently promote ADCC in a human model, applying an autologous system in which physiologic checkpoints are in place. This method provides an alternative approach to potentiate the therapeutic benefit of antitumor Abs that mediate ADCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available